Cannabinoids decrease the th17 inflammatory autoimmune phenotype

Area of Science:

• Immunology
• Pharmacology
• Neuroscience

Background:

• Cannabinoids from Cannabis exhibit anti-inflammatory effects, but their precise mechanisms remain unclear.
• The Th17 cell phenotype is elevated in autoimmune diseases like Multiple Sclerosis, contributing to pathology.

Purpose of the Study:

• To investigate the effects of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on Th17 cell responses.
• To elucidate the mechanisms by which cannabinoids modulate the cytokine milieu in autoimmune conditions.

Main Methods:

• Encephalitogenic T cells were reactivated, inducing Experimental Autoimmune Encephalitis in mice.
• The production and secretion of IL-17, IL-6, IL-10, TNFα, and IFNγ were measured following cannabinoid treatment.
• Receptor involvement (CB1, CB2, PPARγ, 5-HT1A, TRPV1) was assessed.

Main Results:

• THC and CBD significantly suppressed IL-17 production and secretion in a dose-dependent manner.
• Both cannabinoids decreased the mRNA and protein levels of IL-6, a key factor in Th17 induction.
• CBD pretreatment increased anti-inflammatory IL-10 levels, while TNFα and IFNγ remained unaffected.
• Cannabinoid-mediated downregulation of IL-17 did not involve known cannabinoid or related receptors.

Conclusions:

• Cannabinoids uniquely modulate the autoimmune cytokine profile by suppressing pathogenic IL-17 and IL-6.
• These compounds enhance the expression of the anti-inflammatory cytokine IL-10.
• The findings suggest a novel therapeutic potential for cannabinoids in autoimmune diseases by rebalancing the immune response.